



Oct 27, 2023

Company Name:	GNI Group Ltd.
Representative:	Director, Representative Executive Officer, President and CEO Ying Luo, PhD (Security Code: 2160, TSE Growth)
Contact Person:	Chief Financial Officer Toshiya Kitagawa (TEL. 03-6214-3600)

### **Catalyst Biosciences Files 2023Q3 Financial Statements**

GNI Group Ltd., (TSE Growth listed code: 2160; “the Company” or “we”) today announced that Catalyst Biosciences, Inc., (“CBIO”), currently an equity method affiliate of the Company and listed on The Nasdaq Stock Market in the US, has filed the following Form 10-Q with the U.S. Securities and Exchange Surveillance Commission.

<https://ir.catalystbiosciences.com/node/15296/html>

The financial figures in these disclosures are subject to the equity method in the consolidated financial results for Q3 FY2023 as they have been in the past. As disclosed on October 24, 2023, the transaction between CBIO and the Group is expected to close by October 30, after which CBIO will be fully consolidated in our consolidated financial statements.

We will disclose any new material progress as appropriate.

The impact on the Company's financial results for the current fiscal year will be immaterial.

---

This material contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (“the Company”). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as “believe,” “plan,” “strategy,” “expect,” “forecast,” “possibility” and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of the Company, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

The information contained in this material does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any

offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of the Company must be based wholly on the information contained in the preliminary offering circular issued or to be issued by the Company in connection with any such offer and not on the contents hereof.